Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana

It’s been more than a year since Johnson & Johnson trotted out results showing Invokana could improve heart safety for Type 2 diabetes patients. And as of Tuesday, the company’s reps can finally tout those benefits.